Development of ACE2 autoantibodies after SARS-CoV-2 infection is a research paper published in PLoS ONE (2021). On theSindex it has a DataRank of 0. It has been cited 207 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Center for Advancing Translational Sciences
Grant: UL1 TR003107
National Center for Advancing Translational Sciences
Grant: KL2 TR003108
National Center for Advancing Translational Sciences
Grant: TL1 TR003109
National Institute of General Medical Sciences
Grant: P20 GM103625
university of arkansas for medical sciences
Grant: AWD00054193
FWCI
9.73
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Enhancement of NETosis by ACE2-cross-reactive anti-SARS-CoV-2 RBD antibodies in patients with COVID-19
Additional file 1 of Enhancement of NETosis by ACE2-cross-reactive anti-SARS-CoV-2 RBD antibodies in patients with COVID-19